Norcantharidin attenuates tubulointerstitial fibrosis in rat models with diabetic nephropathy

Renal Failure

Volumn 33, Issue 2, 2011, Pages 233-241

  Li, Ying ^a,b   Chen, Qiong ^a,b,c   Liu, Fu You ^a,b   Peng, You Ming ^a,b   Hou, Tao ^a,b   Duan, Shao Bin ^a,b   Li, Jun ^a,b   Luo, Jun Hui ^a,b   Sun, Lin ^a,b   Ling, Guang Hui ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Key Laboratory of Nephrology and Blood Purification in Hunan   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

calcineurin; collagen IV; diabetic nephropathy; FN; norcantharidin; TGF 1; tubulointerstitial fibrosis

Indexed keywords

CALCINEURIN; CITRATE SODIUM; COLLAGEN TYPE 4; GLUCOSE; NORCANTHARIDIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL TISSUE; ARTICLE; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG MECHANISM; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; TUBULOINTERSTITIAL FIBROSIS;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CALCINEURIN; COLLAGEN TYPE IV; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EVALUATION, PRECLINICAL; FIBRONECTINS; FIBROSIS; KIDNEY; MALE; NEPHRITIS, INTERSTITIAL; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79951972078     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.553305     Document Type: Article

References (22)

1. Magri CJ, Fava S. The role of tubular injury in diabetic nephropathy. Eur J Intern Med. 2009;20(6):551-555.
2. Hills CE, Squires PE. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol. 2010;31(1):68-74.
3. Balakumar P, Arora MK, Ganti SS, et al. Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions. Pharmacol Res. 2009; 60(1):24-32.
4. Liu FY, Li Y, Peng YM, et al. Noncantharidin ameliorates proteinuria, associated tubulointerstitial inflammation and fibrosis in protein overload nephropathy. Am J Nephrol. 2008;28(3):465-477. (Pubitemid 351501613)
5. Liu FY, Sun Y, Sun L, et al. Noncantharidin inhibits tubular epithelial mesenchymal transition by downregulating activation of Smad2/3 and snail. ASN Renal Week. 2009;abstract (number: 550493).
6. Katz A, Caramori ML, Sisson-Ross S, et al. An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int. 2002; 61(6):2058-2066.
7. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556-563.
8. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007;27(2):195-207. (Pubitemid 46550314)
9. Parving H-H, Gall M-A, Skøtt P, et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int. 1992;41:758-762.
10. Gambara V, Mecca G, Remuzzi G, et al. Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol. 1993;3(8):1458-1466.
11. Massicot F, Dutertre-Catella H, Pham-Huy C, et al. In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and nor-cantharidin. Basic Clin Pharmacol Toxicol. 2005;96(1):26-32. (Pubitemid 40260843)
12. Huang Y, Liu Q, Liu K, et al. Suppression of growth of highly-metastatic human breast cancer cells by norcantharidin and its mechanisms of action. Cytotechnology. 2009;59(3):209.
13. Huang Y, Liu Q, Liu K, et al. Suppression of growth of highly-metastatic human breast cancer cells by norcantharidin and its mechanisms of action. Cytotechnology. 2009;59(3):201-208.
14. Hill TA, Stewart SG, Ackland SP, et al. Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation. Bioorg Med Chem. 2007;15(18):6126-6134. (Pubitemid 47088962)
15. Bertini I, Calderone V, Fragai M, et al. Structural basis of serine/threonine phosphatase inhibition by the archetypal small molecules cantharidin and norcantharidin. J Med Chem. 2009;52(15):4838-4843.
16. Baba Y, Hirukawa N, Tanohira N, et al. Structure-based design of a highly selective catalytic site-directed inhibitor of Ser/Thr protein phosphatase 2B (calcineurin). J Am Chem Soc. 2003;125(32):9740-9749. (Pubitemid 36975936)
17. Baba Y, Hirukawa N, Sodeoka M. Optically active cantharidin analogues possessing selective inhibitory activity on Ser/ Thr protein phosphatase 2B (calcineurin): Implications for the binding mode. Bioorg Med Chem. 2005;13(17):5164-5170. (Pubitemid 41039976)
18. Tumlin JA, Someren JT, Swanson CE, et al. Expression of calcineurin activity and -subunit isoforms in specific segments of the rat nephron. Am J Physiol Renal Physiol. 1995;269(4 pt. 2):F558-F563.
19. Gooch JL. An emerging role for calcineurin A in the development and function of the kidney. Am J Physiol Renal Physiol. 2006;290(4):769-776.
20. Cobbs SL, Gooch JL. NFATc is required for TGF beta-mediated transcriptional regulation of fibronectin. Biochem Biophys Res Commun. 2007;362(2):288-294. (Pubitemid 47332403)
21. Gooch JL, Barnes JL, Garcia S, et al. Calcineurin is activated in diabetes and is required for glomerular hypertrophy and ECM accumulation. Am J Physiol Renal. 2003;284(1):144-154.
22. Gooch JL, Gorin Y, Zhang BX, et al. Involvement of calcineurin in transforming growth factor-b mediated regulation of extracellular matrix accumulation. J Biol Chem. 2004; 279(15):15561-15570. (Pubitemid 38618957)